Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects With Chronic Antibiotic-resistant Pouchitis

Next Previous
X
Search
Trial Profile

A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects With Chronic Antibiotic-resistant Pouchitis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMT 101 (Primary)
  • Indications Pouchitis
  • Focus Therapeutic Use
  • Acronyms FILLMORE
  • Sponsors Applied Molecular Transport

    • Most Recent Events

    • 03 Mar 2023 Additional data results presented in an Applied Molecular Transport media release.
    • 03 Mar 2023 According to an Applied Molecular Transport media release, additional data results of this study presented at the European Crohn's and Colitis Organisation (ECCO) '23 Congress.
    • 22 Dec 2022 According to an Applied Molecular Transport media release, additional data will be presented at the European Crohn's and Colitis Organisation meeting in March 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top